๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia

โœ Scribed by David Dingli; Ayalew Tefferi

Book ID
107540151
Publisher
Current Science Inc.
Year
2006
Tongue
English
Weight
103 KB
Volume
1
Category
Article
ISSN
1558-8211

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

New drugs in essential thrombocythemia a
New drugs in essential thrombocythemia and polycythemia vera
โœ A. Tefferi; M.A. Elliott; L.A. Solberg Jr; M.N. Silverstein ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 996 KB

Among the chronic myeloproliferative disorders, polycythemia vera and essential thrombocythemia are unique because of their association with thrombohemorrhagic manifestations and their relatively indolent clinical course. Patients with essential thrombocythemia may not have a significant shortening

Leukemogenic risk of hydroxyurea therapy
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
โœ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 417 KB ๐Ÿ‘ 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a